ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Systemic and local dysregulation of the complement system in glioma: a comprehensive systematic review.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGliomas, particularly glioblastoma (GBM), are characterized by aggressive progression and profound immune evasion. The complement system which is a fundamental component of innate immunity comprising classical, alternative, and lectin activation pathways converging on target cell lysis, is frequently dysregulated within the tumor microenvironment, where it plays a pivotal role in promoting tumor survival and immune shielding. The complement system, often dysregulated in the tumor microenvironment, plays a pivotal role in these processes via regulators like Factor H (CFH), Factor I (CFI), and Clusterin (CLU). This systematic review analyzes their expression, regulation, and dual roles in immune shielding and oncogenic signaling.
methodsA systematic review was conducted following PRISMA 2020 guidelines. Major databases (PubMed, Scopus, Embase, Web of Science) were searched up to November 2025. Eligible studies included in vitro, in vivo, and clinical investigations of complement regulators in glioma.
resultsTwenty-one experimental studies met inclusion criteria, demonstrating that glioma cells actively synthesize, secrete, and epigenetically regulate complement inhibitors to subvert immune surveillance. Soluble regulators such as CFH, FHL-1, and FHR5 bind to tumor cell surfaces, accelerate convertase decay, and protect cells from complement-mediated cytolysis. Mechanistically, the review identified critical "non-canonical" oncogenic functions beyond immune shielding. CFH acts as a novel ligand for the ICOS receptor on regulatory T cells, activating the PI3K/Akt pathway to enhance immunosuppression, while circ-CFH sponges miR-149 to drive AKT1-mediated proliferation. Factor I is similarly upregulated in high-grade gliomas, promoting tumor invasion via VEGF-FAK signaling. Clusterin plays a pivotal role in therapeutic resistance; glioblastoma stem-cell-derived extracellular vesicles transfer Clusterin to macrophages, inducing M2 polarization and conferring resistance to temozolomide. Furthermore, Clusterin silencing sensitizes glioma cells to senolytic therapy by triggering oxidative stress and apoptosis. Among membrane-bound regulators, CD59 was identified as the dominant inhibitor of the terminal lytic complex, surpassing CD46 in functional importance.
conclusionComplement regulators in glioma extend beyond passive immune evasion to actively drive tumorigenesis and therapeutic resistance. The identification of non-canonical mechanisms, such as the CFH-ICOS axis and Clusterin-mediated drug resistance, highlights these proteins as critical prognostic biomarkers and promising therapeutic targets to sensitize tumors for efficient immune and chemotherapy.
Indexed as
Identifiers
42627589What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.